Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
06/2003
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109673 Regulation of human hm74-like g protein coupled receptor
06/12/2003US20030109672 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109670 Conotoxins; sodium channel moderators, calcium channel blockers, analgesics
06/12/2003US20030109483 A purified Parapoxvirus ovis envelope protein termed "B2L" can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response
06/12/2003US20030109482 Reagents can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancer,
06/12/2003US20030109477 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
06/12/2003US20030109475 Introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or
06/12/2003US20030109469 Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
06/12/2003US20030109464 Galectins -1 and -4 in tumor development
06/12/2003US20030109455 HEPTA-, OCTA-and nonapeptides having antiangiogenic activity
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109451 Human arsenite-resistance protein
06/12/2003US20030109450 Useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109447 Methods of use of recombinant vasoactive protein from salivary gland of the black fly
06/12/2003US20030109445 Methods and compositions for the treatment and prevention of parkinson's disease
06/12/2003US20030109444 Bone anti-resorptive compounds
06/12/2003US20030109443 Determining the prognosis for treatment of, and methods for identifying candidate compounds for treating, stabilizing, or preventing cancer, for example, endometrial cancer. These methods utilize the novel tumor suppressor protein, Cables.
06/12/2003US20030109440 Directed to nucleic acids encoding GRB7, which is involved in modulation of T lymphocyte activation and TCR signaling. The invention further relates to methods for identifying and using agents, including small organic molecules, peptides, circular
06/12/2003US20030109439 Keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163 in lower concentrations
06/12/2003US20030109438 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109434 One or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expression such
06/12/2003US20030109431 Synthetic tetrapeptide having an amino acide sequence, Glycine- Proline-Arginine-Proline (GPRP) has pro-inflammatory effects on human fibroblastic cells, including synovial cells. An amide analog of GPRP is ineffective in inducing, or
06/12/2003US20030109430 Immunoassays for human and canine brain natriuretic peptide
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109428 Novel molecules of the card-related protein family and uses thereof
06/12/2003US20030109423 Cyclin- dependent kinases (Cdks) are important for driving cells through different phases of the cell cycle and their sequential activation and deactivation are tightly regulated activation of the mitotic Cdk, Cdc2, requires multiple events;
06/12/2003US20030109419 Detection and tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030109044 Methods of using 279, a human G protein-coupled protein receptor
06/12/2003US20030109033 Feline calicivirus genes and vaccines in particular recombinant vaccines
06/12/2003US20030109027 Tumor suppression genes
06/12/2003US20030109026 Genetically modified tumor-targeted bacteria with reduced virulence
06/12/2003US20030109024 Translation of messenger Rna; genetic engineering protein
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030109008 Cell proliferation, cell differentiation; stem cells
06/12/2003US20030109004 Culture product; cell transformation; genetic engineering using promoter
06/12/2003US20030109003 Antitumor agent; transformation of expression vector; genetic engineering; process control hybrids
06/12/2003US20030109002 SIRP proteins and uses thereof
06/12/2003US20030109001 Genetic engineering in prokaryotic cells; diagnosis of autoimmune disease using antibodies
06/12/2003US20030109000 Culture product; binding polypeptides containing activated end groups
06/12/2003US20030108999 Cell having amplified signal transduction pathway responses and uses therefor
06/12/2003US20030108996 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030108995 Polypeptide containing high concentration of leucine; antiinflammatory, anticancer agent
06/12/2003US20030108994 Antibodies that bind human Zven1
06/12/2003US20030108993 Human mitochondrial chaperone protein
06/12/2003US20030108992 Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
06/12/2003US20030108989 Mixture of genetic engineered protein and carrier; trauma therapy for humans, animals
06/12/2003US20030108987 Controlling gene expression; ligand activation; prevent cysts formation in nematodes
06/12/2003US20030108986 Contacting protein with labeled angiopeptin; measuring binding
06/12/2003US20030108985 Structure for presenting desired peptide sequences
06/12/2003US20030108984 CD44 splice variant associated with rheumatoid arthritis
06/12/2003US20030108983 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030108974 Analyzing antibodies for hepatitis C virus using peptide antigen
06/12/2003US20030108970 Generating antibodies; quantitative analysis
06/12/2003US20030108965 Using polypeptide, detection of antibody; cancer of ovaries
06/12/2003US20030108964 Caspase-inhibitory-factor(cif)and uses thereof
06/12/2003US20030108963 Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
06/12/2003US20030108961 Methods and compositions for diagnosing breast cancer
06/12/2003US20030108960 Detection antigens to Trypanosoma; antiprotozoa agent; sensitive, accurate analysis
06/12/2003US20030108958 Controlling gene expression; antiinflammatory agents, anticancer agents, autoimmune disease
06/12/2003US20030108957 Biocidal molecules, macromolecular targets and methods of production and use
06/12/2003US20030108956 Measurement, calibration of potassium channel moderators
06/12/2003US20030108953 Truncated egf receptor
06/12/2003US20030108951 Screening drugs using antigens; suppress gene expression
06/12/2003US20030108950 Measuring concentration in body fluid of tumor antibodies
06/12/2003US20030108948 Artificial antibody polypeptides
06/12/2003US20030108932 Ras guanine-nucleotide-exchange factor 1 (nrg1)
06/12/2003US20030108931 Calibration gene expression; amplification
06/12/2003US20030108929 Diagnosis of Alzheimer's disease
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108924 Isolated polynucleotide; determination genotype; analyzing
06/12/2003US20030108920 Tumor suppressor-like proteins that bind IGFBP2
06/12/2003US20030108912 Liver enriched transcription factor
06/12/2003US20030108909 Genetic suppressor elements against human immunodeficiency virus
06/12/2003US20030108907 Nucleic acids, proteins, and antibodies
06/12/2003US20030108906 Signal transduction, gene expression of pain sequences; genetic engineering
06/12/2003US20030108904 Novel scavenger receptors
06/12/2003US20030108887 Zinc finger proteins; genomes
06/12/2003US20030108885 Methods and compositions for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs
06/12/2003US20030108882 Nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid
06/12/2003US20030108880 Gene expression regulation
06/12/2003US20030108873 Systems for the detection of target sequences
06/12/2003US20030108869 Leucine zipper domains of reporter molecule hydrolyze penicillin or cephalosporin substrates; gene expression
06/12/2003US20030108863 Nodavirus-like DNA expression vector and uses therefor
06/12/2003US20030108858 Methods for the simultaneous detection of HCV antigens and HCV antibodies
06/12/2003US20030108857 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
06/12/2003US20030108572 Antigenic preparations and the isolation of such preparations
06/12/2003US20030108570 Method and kit using recombinant proteins in fusion of porcine reproductive and respiratory syndrome virus and for diagnosis
06/12/2003US20030108568 Antidiabetic agents
06/12/2003US20030108567 Antidiabetic agents
06/12/2003US20030108566 Dimeric flourescent polypeptides
06/12/2003US20030108564 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus
06/12/2003US20030108563 Blood screening for hepatitis C virus; complexing
1 ... 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 ... 2916